The MIRACLE trial [21] also demonstrated that PFS was significantly prolonged by combination therapy of everolimus and endocrine therapy, compared to endocrine therapy alone (19.4 vs. 12.9 months) in premenopausal patients with HR‐positive/HER2‐negative advanced breast cancer who had experienced treatment failure with endocrine therapy (Table 2). Here, ERBB2 is linked to breast carcinoma.